Chris Lancaster

Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in <i>Clostridioides difficile</i> Infection

Anne J Gonzales-Luna, Abiola Olumuyiwa Olaitan, Wan‐Jou Shen et al. · Open Forum Infectious Diseases · 2021 · 39 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +13

Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with <i>Clostridioides difficile</i> Infection: A Phase 2a Multicenter Clinical Trial

Kevin W. Garey, Jacob McPherson, An Q Dinh et al. · Clinical Infectious Diseases · 2022 · 38 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection

Travis J Carlson, Bradley T. Endres, Julie Le Pham et al. · Open Forum Infectious Diseases · 2020 · 33 citations · Full text

Life Sciences, Infectious Diseases, Clinical Epidemiology +12

PCR ribotypes of <i>Clostridioides difficile</i> across Texas from 2011 to 2018 including emergence of ribotype 255

Anne J Gonzales-Luna, Travis J Carlson, Kierra M. Dotson et al. · Emerging Microbes & Infections · 2020 · 31 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects

Kevin W. Garey, Khurshida Begum, Chris Lancaster et al. · Journal of Antimicrobial Chemotherapy · 2020 · 23 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14